Back

The effect of rhythm control for atrial fibrillation on coexisting secondary mitral valve regurgitation: initial results from a large, real-world registry

14 April 2026 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation catheter ablation Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Moritz Nies

The University Medical Center Hamburg-Eppendorf, Hamburg (Germany)

5 More presentations in this session

Presentation thumbnail
Autonomic profile changes after pulsed-field versus thermal ablation in patients with atrial fibrillation: a systematic review and meta-analysis
Doctor I. Antoun (Leicester, GB)
Abstract Slides Video
Presentation thumbnail
TiFFANY-CF: fatal outcomes after atrial fibrillation ablation using contact force-sensing vs. non-contact force catheters - an FDA MAUDE database analysis
Ms M. Markgraf (Luebeck, DE)
Abstract Slides Video
Presentation thumbnail
Novel AI-based physiological tracking of waves in atrial fibrillation identify active pulmonary veins, non-PV sites of termination
Doctor S. Ruiperez-Campillo (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Automated CT-derived assessment of left atrial wall thickness before and after pulsed-field and radiofrequency ablation for atrial fibrillation
Mr S. Gribissa (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Quantification of reversible electroporation area following pentaspline vs balloon-in-basket pulsed-field ablation in patients undergoing systematic remapping
Doctor I. Lopez Alacid (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation catheter ablation

The Event

Event poster

EHRA 2026

14 April 2026 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Mitral regurgitation decreases over time after successful thoracoscopic ablation, a subanalysis of a prospective cohort study.
thumbnail
Congress Presentation
Radiofrequency catheter ablation is associated with reduced cardiovascular events in atrial fibrillation patients with mitral regurgitation
thumbnail
Congress Presentation
Atrial fibrillation treatment paradigm in patients with mitral regurgitation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources